Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On October 28, 2025, Edesa Biotech, Inc. (EDSA) announced positive results from a Phase 3 clinical trial evaluating paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS).</li><li>EB05 met both the primary and secondary endpoints of the study, which included a statistically significant and clinically meaningful 25% relative risk reduction in the risk of death compared to placebo (P<0.001).</li><li>Across the 275 patients that were enrolled for the Phase 2 and Phase 3 studies, EB05 was generally well-tolerated and consistent with the observed safety profile to date.</li></ul>

On October 28, 2025, Edesa Biotech, Inc. (EDSA) announced positive results from a Phase 3 clinical trial evaluating paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS).EB05 met both the primary and secondary endpoints of the study, which included a statistically significant and clinically meaningful 25% relative risk reduction in the risk of death compared to placebo (PAcross the 275 patients that were enrolled for the Phase 2 and Phase 3 studies, EB05 was generally well-tolerated and consistent with the observed safety profile to date.

EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial 